Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2006

View Archived Issues

Seroconversion seen with hepatitis B vaccine in phase IIa trial

Proapoptotic activity of a novel derivative of shikonin

Phase II study of NPI-32101 completes enrollment

Xoma and Aveo sign agreement to humanize AV-299

Senesco's Factor 5A inhibits tumor development in mice

AERx iDMS phase III program set to reopen

Angiogenic factors mediate the cardioprotective properties of sildenafil citrate

GLOBE study reveals resistance and efficacy with telbivudine in hepatitis B

Studies assess ranibizumab alone and with verteporfin PTD in macular degeneration

Emisphere to receive milestone payment for use of eligen in Novartis program

Inhibitex continues Veronate review

Amicus files to begin phase I studies of AT-2101 in Gaucher's disease

BioTie grants Britannia nalmefene marketing rights for U.K. and Ireland

Enrollment completed in phase III study of Corlux in psychotic major depression

Spanish companies establish consortium, Genius Pharma

Enrollment completed in phase IIb obesity study of AOD-9604

Oral direct thrombin inhibitor MPC-0920 begins phase I study

Phase III studies of tapentadol set for Q3

Phase I trial evaluates ENMD-1198 in patients with advanced cancer

Pharmaxis completes end of phase II meeting for Bronchitol

Encouraging findings from phase I study of PV-10 in recurrent breast cancer

Phase Ib/II trial studies CTCE-9908 in patients with late-stage cancers

NDA for controlled-release zileuton targeted for Q3

TNX-355 produces durable viral-load suppression in HIV patients

E.U. approval for NovoMix 30 label extension

Dacogen approved for myelodysplastic syndromes

Novel antiinfective agents revealed in recent patents

Anti-HIV agents reported in recent patent literature

Mount Sinai researchers identify important regulator of postmenopausal bone loss

RTK inhibition reduces retinal vascular permeability in animal models of diabetic macular edema

Silencing RTP801 gene with novel siRNA shows benefit in a murine model of CNV

Snapshots of recent studies on VEGF Trap presented at the ARVO meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...